Article
Medicine, General & Internal
Jung Won Chun, Boyoung Lee, Weon Seo Park, Nayoung Han, Eun Kyung Hong, Eun Young Park, Sung Sik Han, Sang-Jae Park, Tae Hyun Kim, Woo Jin Lee, Sang Myung Woo
Summary: The study aimed to investigate the predictive and prognostic values of several biomarkers in patients with advanced biliary tract cancer treated with gemcitabine plus cisplatin. The results showed that increased intratumoral expression of RRM1 may predict poor survival in patients with this chemotherapy regimen.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Tatsuya Ioka, Masashi Kanai, Shogo Kobayashi, Daisuke Sakai, Hidetoshi Eguchi, Hideo Baba, Satoru Seo, Akinobu Taketomi, Tadatoshi Takayama, Hiroki Yamaue, Masahiro Takahashi, Masayuki Sho, Keiko Kamei, Jiro Fujimoto, Masanori Toyoda, Junzo Shimizu, Takuma Goto, Yoshitaro Shindo, Kenichi Yoshimura, Etsuro Hatano, Hiroaki Nagano
Summary: This study demonstrates that adding S-1 to GC can improve overall survival and response rate in patients with advanced biliary tract cancer, making GCS a potential new first-line standard chemotherapy. Additionally, GCS is being tested in a neoadjuvant trial to further evaluate its efficacy.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES
(2023)
Article
Medicine, General & Internal
Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, Richard S. Finn, Junji Furuse, Zhenggang Ren, Thomas Yau, Heinz-Josef Klumpen, Stephen L. Chan, Masato Ozaka, Chris Verslype, Mohamed Bouattour, Joon Oh Park, Olga Barajas, Uwe Pelzer, Juan W. Valle, Li Yu, Usha Malhotra, Abby B. Siegel, Julien Edeline, Arndt Vogel
Summary: This study examined the efficacy of adding the immune checkpoint inhibitor pembrolizumab to the standard chemotherapy regimen for advanced biliary tract cancer. The results showed that the combination treatment significantly improved overall survival compared to chemotherapy alone.
Article
Oncology
Mark K. Doherty, Vincent C. Tam, Mairead G. McNamara, Raymond Jang, David Hedley, Eric Chen, Neesha Dhani, Patricia Tang, Hao-Wen Sim, Grainne M. O'Kane, Stephanie DeLuca, Lisa Wang, Theresa Pedutem, Jennifer J. Knox
Summary: The addition of sequential or continuous selumetinib to cisplatin and gemcitabine failed to improve efficacy and increased toxicity in patients with advanced biliary tract cancer.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Christian Mueller, Jazan Omari, Konrad Mohnike, Caroline Baer, Maciej Pech, Verena Keitel, Marino Venerito
Summary: Personalized treatment based on multidisciplinary discussion is crucial for improving survival and ensuring safety in patients with progressing unresectable biliary tract cancer.
Article
Oncology
Hiroto Inoue, Akiko Todaka, Kentaro Yamazaki, Kunihiro Fushiki, Hiromichi Shirasu, Takeshi Kawakami, Takahiro Tsushima, Satoshi Hamauchi, Tomoya Yokota, Nozomu Machida, Akira Fukutomi, Yusuke Onozawa, Akira Andoh, Hirofumi Yasui
Summary: This retrospective study analyzed the efficacy and safety of S-1 as a second-line therapy following GC in 116 patients with unresectable or recurrent BTC. The results indicated that the efficacy and safety of S-1 following GC were comparable to S-1 following GEM monotherapy.
INVESTIGATIONAL NEW DRUGS
(2021)
Article
Gastroenterology & Hepatology
Mitesh J. Borad, Li-Yuan Bai, Donald Richards, Kabir Mody, Joleen Hubbard, Sun Young Rha, John Soong, Daniel McCormick, Emmett Tse, Daniel O'Brien, Ahmad Bayat, Daniel Ahn, S. Lindsey Davis, Joon Oh Park, Do-Youn Oh
Summary: This study investigates the safety and efficacy of silmitasertib in combination with gemcitabine and cisplatin for the treatment of cholangiocarcinoma. The results show promising preliminary evidence of efficacy for the first-line treatment of locally advanced/metastatic cholangiocarcinoma.
Article
Oncology
Hyehyun Jeong, Jae Ho Jeong, Kyu-Pyo Kim, Sang Soo Lee, Dong Wook Oh, Do Hyun Park, Tae Jun Song, Yangsoon Park, Seung-Mo Hong, Baek-Yeol Ryoo, Changhoon Yoo
Summary: Unresectable or metastatic biliary tract cancer (BTC) has a poor prognosis with the standard gemcitabine and cisplatin (GemCis) regimen, but HER2-targeted therapy shows promising preliminary feasibility in patients with HER2-positive advanced BTC. This prospective study suggests the potential benefits of HER2-targeted combination chemotherapy in improving outcomes for patients with advanced BTC, warranting further investigation through future prospective randomised trials.
Article
Multidisciplinary Sciences
Tian-mei Zeng, Guang Yang, Cheng Lou, Wei Wei, Chen-jie Tao, Xi-yun Chen, Qin Han, Zhuo Cheng, Pei-pei Shang, Yu-long Dong, He-ming Xu, Lie-ping Guo, Dong-sheng Chen, Yun-jie Song, Chuang Qi, Wang-long Deng, Zhen-gang Yuan
Summary: This study is a phase II clinical trial investigating the efficacy of the anti-PD-1 antibody sintilimab in combination with chemotherapy as first-line treatment for patients with advanced biliary tract cancers. The primary endpoint was overall survival, and secondary endpoints included toxicities, progression-free survival, and objective response rate.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Sung Hwan Lee, Jaekyung Cheon, Seoyoung Lee, Beodeul Kang, Chan Kim, Hyo Sup Shim, Young Nyun Park, Sanghoon Jung, Sung Hoon Choi, Hye Jin Choi, Choong-kun Lee, Hong Jae Chon
Summary: The study identified that ARID1A alteration predicts the response and resistance to chemotherapy in advanced biliary tract cancer, and patients with ARID1A alteration have worse clinical outcomes.
CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Nicolas Roussot, Julie Vincent, Remi Palmier, Guillaume Constantin, Leila Bengrine, Jean-David Fumet, Francois Ghiringhelli
Summary: This study assessed the efficacy and safety of second-line FOLFIRI combined with bevacizumab for advanced biliary tract cancer. The results showed promising tumor response rate and a modest improvement in overall survival.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Shozo Mori, Taku Aoki, Takayuki Shiraki, Takayuki Shimizu, Takamune Yamaguchi, Kyung-Hwa Park, Takatsugu Matsumoto, Yuhki Sakuraoka, Yukihiro Iso, Keiichi Kubota
Summary: This study found that adjuvant chemotherapy with gemcitabine plus cisplatin is associated with better outcomes and good tolerability in patients with biliary tract cancer who have undergone major hepatectomy.
ANTICANCER RESEARCH
(2021)
Article
Medicine, Research & Experimental
Chiao-Ping Chen, Chun-Nan Yeh, Yi-Ru Pan, Wen-Kuan Huang, Yu-Tien Hsiao, Chih-Hong Lo, Chiao-En Wu
Summary: The combination treatment of MK1775 and gemcitabine enhances the therapeutic potential for biliary tract cancer (BTC) by inducing DNA damage response and apoptosis, regardless of p53 status.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Medicine, Research & Experimental
Chiao-Ping Chen, Chun-Nan Yeh, Yi-Ru Pan, Wen-Kuan Huang, Yu-Tien Hsiao, Chih-Hong Lo, Chiao-En Wu
Summary: The combination of gemcitabine and MK1775 shows enhanced cytotoxicity against BTC cells, regardless of p53 status. The combination treatment inhibits the growth of BTC tumors through inducing a DNA damage response and apoptosis. This preclinical study provides a basis for future clinical trials of gemcitabine plus MK1775 in patients with BTC.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Oncology
In Sil Choi, Ki Hwan Kim, Ju Hyun Lee, Koung Jin Suh, Ji-Won Kim, Jin Hyun Park, Yu Jung Kim, Jin-Soo Kim, Jee Hyun Kim, Jin Won Kim
Summary: The study found that in the second-line treatment of biliary tract cancer, irinotecan/5-fluorouracil (mFOLFIRI) was not superior to oxaliplatin/5-fluorouracil (mFOLFOX), but both showed comparable efficacy and tolerability. Adverse events differed between the two treatment arms.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Mairead G. McNamara, John Bridgewater, Daniel H. Palmer, Olusola Faluyi, Harpreet Wasan, Alkesh Patel, William D. Ryder, Safia Barber, Chathunissa Gnanaranjan, Essam Ghazaly, T. R. Jeff Evans, Juan W. Valle
Summary: The combination of NUC-1031 with cisplatin in the treatment of advanced biliary tract cancer (ABC) showed favorable safety profile in the initial study, with 725 mg/m(2) NUC-1031 recommended for phase III trial evaluation with cisplatin.
Article
Oncology
Richard A. Adams, David J. Fisher, Janet Graham, Jenny F. Seligmann, Matthew Seymour, Richard Kaplan, Emma Yates, Mahesh Parmar, Susan D. Richman, Philip Quirke, Rachel Butler, Ewan Brown, Fiona Collinson, Stephen Falk, Harpreet Wasan, Kai-Keen Shiu, Gary Middleton, Leslie Samuel, Richard H. Wilson, Louise C. Brown, Timothy S. Maughan
Summary: Despite strong evidence of disease control with maintenance therapy, overall survival (OS) remains unaffected. The FOCUS4-N trial demonstrated significant efficacy in progression-free survival (PFS) with maintenance capecitabine therapy, but no significant improvement in OS. Toxicity between the capecitabine and active monitoring groups was comparable, with expected side effects such as fatigue, diarrhea, and hand-foot syndrome.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Jenny F. Seligmann, David J. Fisher, Louise C. Brown, Richard A. Adams, Janet Graham, Philip Quirke, Susan D. Richman, Rachel Butler, Enric Domingo, Andrew Blake, Emma Yates, Michael Braun, Fiona Collinson, Rob Jones, Ewan Brown, Emma de Winton, Timothy C. Humphrey, Mahesh Parmar, Richard Kaplan, Richard H. Wilson, Matthew Seymour, Timothy S. Maughan
Summary: In the FOCUS4 trial, adavosertib showed potential as a well-tolerated therapy for RAS/TP53-mutant mCRC, with significant improvement in progression-free survival (PFS) compared to active monitoring (AM). However, there was no significant improvement in overall survival (OS), and the activity of adavosertib was higher in left-sided tumors compared to right-sided tumors. Further testing is needed in this population with unmet needs.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Oncology
J. Tabernero, L. Velez, T. L. Trevino, A. Grothey, R. Yaeger, E. Van Cutsem, H. Wasan, J. Desai, F. Ciardiello, T. Yoshino, A. Gollerkeri, K. Maharry, J. Christy-Bittel, S. Kopetz
Summary: Colorectal cancer is the second leading cause of cancer deaths worldwide, with a 5-year relative survival rate of 14% in patients with metastatic colorectal cancer (mCRC). BRAF V600E mutations, found in about 10%-15% of mCRC patients, are associated with a poorer prognosis. The combination therapy of encorafenib and cetuximab is the only approved chemotherapy-free targeted treatment for previously treated patients with BRAF V600E-mutated mCRC in the USA and Europe, and it has a distinct safety profile with reported adverse events like dermatologic, gastrointestinal, and renal events, as well as pyrexia and secondary skin malignancies.
Article
Oncology
P. J. Ross, H. S. Wasan, D. Croagh, M. Nikfarjam, N. Nguyen, M. Aghmesheh, A. M. Nagrial, D. Bartholomeusz, A. Hendlisz, T. Ajithkumar, C. Iwuji, N. E. Wilson, D. M. Turner, D. C. James, E. Young, M. T. Harris
Summary: This study suggests that combining P-32 microparticles with standard-of-care chemotherapy may have clinically relevant benefits for patients with unresectable locally advanced pancreatic cancer. The treatment has an acceptable safety profile and results in improved local disease control and overall survival.
Article
Oncology
E. Van Cutsem, I Danielewicz, M. P. Saunders, P. Pfeiffer, G. Argiles, C. Borg, R. Glynne-Jones, C. J. A. Punt, A. J. Van de Wouw, M. Fedyanin, D. Stroyakovskiy, H. Kroening, P. Garcia-Alfonso, H. Wasan, A. Falcone, R. Fougeray, A. Egorov, N. Amellal, V Moiseyenko
Summary: The TASCO1 trial evaluated the use of trifluridine/tipiracil plus bevacizumab (TT-B) in patients with unresectable metastatic colorectal cancer (mCRC) ineligible for intensive chemotherapy, and the results showed that TT-B has potential therapeutic benefits.
BRITISH JOURNAL OF CANCER
(2022)
Letter
Dermatology
Yasmin Alfallouji, Ashley Spencer, Eduardo Calonje, Conal M. Perrett, Richard Watchorn, Catherine Borysiewicz, Tara Hodgkinson, Harpreet Wasan, Christopher B. Bunker, Rachel U. Sidwell
Summary: This article describes two cases of eruptive naevi secondary to encorafenib used for the treatment of BRAF-mutant metastatic colorectal cancer.
CLINICAL AND EXPERIMENTAL DERMATOLOGY
(2022)
Article
Oncology
John Bridgewater, Peter Fletcher, Daniel H. Palmer, Hassan Z. Malik, Raj Prasad, Darius Mirza, Alan Anthony, Pippa Corrie, Stephen Falk, Meg Finch-Jones, Harpreet Wasan, Paul Ross, Lucy Wall, Jonathan Wadsley, Thomas R. Evans, Deborah Stocken, Clive Stubbs, Raaj Praseedom, Yuk Ting Ma, Brian Davidson, John Neoptolemos, Tim Iveson, David Cunningham, O. James Garden, Juan W. Valle, John Primrose
Summary: This long-term analysis confirms that capecitabine, as adjuvant therapy, can improve the overall survival of patients with resected biliary tract cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
S. Kopetz, A. Grothey, E. Van Cutsem, R. Yaeger, H. Wasan, T. Yoshino, J. Desai, F. Ciardiello, F. Loupakis, Y. S. Hong, N. Steeghs, T. K. Guren, H-T Arkenau, P. Garcia-Alfonso, A. Belani, X. Zhang, J. Tabernero
Summary: In patients with BRAF V600E metastatic colorectal cancer, encorafenib plus cetuximab with or without binimetinib not only improves overall survival (OS) but also delays the decline in quality of life (QoL).
Review
Oncology
Leyin Zhang, Deyi Shen, Lulin Yu, Yici Yan, Harpreet S. Wasan, Jieru Yu, Shuo Zhang, Leitao Sun
Summary: Antibody-drug conjugates (ADCs) have shown promising efficacy and safety in cancer treatment, but their effectiveness for solid tumors requires further investigation.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2022)
Article
Health Policy & Services
Raymond H. Henderson, Declan French, Ethna McFerran, Richard Adams, Harpreet Wasan, Robert Glynne-Jones, David Fisher, Susan Richman, Philip D. Dunne, Lisa Wilde, Timothy S. Maughan, Richard Sullivan, Mark Lawler
Summary: Health economic analyses compared the cost-effectiveness of intermittent and continuous cetuximab for colorectal cancer patients, showing cost savings and improved quality of life with intermittent treatment. These results helped support policy change, reduce unnecessary treatment, and underscored the importance of treatment breaks in reducing treatment toxicity.
JOURNAL OF CANCER POLICY
(2022)
Letter
Gastroenterology & Hepatology
Tim Meyer, Sevasti Galani, Andre Lopes, Arndt Vogel
JOURNAL OF HEPATOLOGY
(2023)
Article
Health Care Sciences & Services
Andres Tamm, Helen J. S. Jones, William Perry, Des Campbell, Rachel Carten, Jim Davies, Algirdas Galdikas, Louise English, Alex Garbett, Ben Glampson, Steve Harris, Khurum Khan, Stephanie Little, Lee Malcomson, Sheila Matharu, Erik Mayer, Luca Mercuri, Eva J. A. Morris, Rebecca Muirhead, Ruth Norris, Catherine O'Hara, Dimitri Papadimitriou, Niels Peek, Andrew Renehan, Gail Roadknight, Naureen Starling, Marion Teare, Rachel Turner, Kinga A. Varnai, Harpreet Wasan, Kerrie Woods, Chris Cunningham
Summary: This study presents the process of collating colorectal cancer data in the UK and explores the potential use of this data source. By utilizing natural language processing and data integration, longitudinal histories of individual patients can be reconstructed for analysis. The results show that algorithms for analyzing routinely collected data have been refined to provide a rich dataset for researching the natural history, treatment variation, and optimal management of colorectal cancer.
BMJ HEALTH & CARE INFORMATICS
(2022)
Article
Oncology
Gerald Prager, Claus-Henning Koehne, Juan Manuel O'Connor, Fernando Rivera, Daniele Santini, Harpreet Wasan, Jean Marc Phelip
Summary: The SCOPE project aimed to understand practice patterns and treatment choices for patients with mCRC. Results showed that prolonging overall survival was the main goal in first-line treatment, while quality of life was prioritized in third-line treatment. Most participants considered trifluridine-tipiracil as an appropriate third-line treatment option.
Letter
Oncology
Angela Lamarca, Daniel H. Palmer, Harpreet Singh Wasan, Paul J. Ross, Yuk Ting Ma, Arvind Arora, Stephen Falk, Roopinder Gillmore, Jonathan Wadsley, Kinnari Patel, Alan Anthoney, Anthony Maraveyas, Tim Iveson, Justin S. Waters, Claire Hobbs, Safia Barber, W. David Ryder, John Ramage, Linda M. Davies, John A. Bridgewater, Juan W. Valle